Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences/Japan Tobacco

Drug Profile

Cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences/Japan Tobacco

Alternative Names: Elvitegravir/Truvada/GS 9350; EVG/COBI/FTC/TDF; EVG/FTC/TDF/cobicistat FDC Quad tablet; Quad; Stribild

Latest Information Update: 06 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Japan Tobacco
  • Class Antiretrovirals; Deoxyribonucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 05 Dec 2018 Gilead offered Japan Tobacco to terminate the exclusive licenses for HIV drugs
  • 06 Sep 2018 Gilead Sciences completes the WAVES phase IIIb trial in HIV infections (Treatment-naive) in USA, Belgium, Dominican Republic, France, Italy, Mexico, Portugal, Puerto Rico, Thailand, Russia, Uganda and United Kingdom (NCT01705574)
  • 27 Aug 2018 Japan Tobacco and Gilead sign a letter of intent to initiate discussion to terminate license agreement for HIV drugs in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top